FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
FibroGen, Inc. (NASDAQ: FGEN) announced today the start of a randomized, open‑label Phase 2 monotherapy trial...
NASDAQ: FGEN
FibroGen Reports Decline in Sales, Pushes Ahead with Roxadustat and New Drug Development
US-based biotech FibroGen Inc. (NASDAQ: FGEN) released its Q4 and full-year 2024 financial results, showing...
FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included
US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...
FibroGen Inc. Reports 15% YOY Revenue Growth in Q3 2024 Led by Evrenzo
US-based biopharmaceutical company FibroGen Inc. (NASDAQ: FGEN) has released its Q3 2024 financial report, showing...
FibroGen Inc. Enters Restructuring Mode After Late-Stage Trial Failures for Pamrevlumab
US-based biotechnology company FibroGen Inc. (NASDAQ: FGEN), which maintains significant operations in China, is initiating...
Kind Pharmaceuticals Resolves Trade Secrets Dispute with Fibrogen Amid HIF-PHI Pipeline Development
Kind Pharmaceuticals LLC, a Sino-US pharmaceutical company, along with its Chinese affiliate Hangzhou Andao Pharmaceutical...
FibroGen’s Roxadustat Approved in Macau for Chronic Kidney Disease-Related Anemia
FibroGen Inc. (NASDAQ: FGEN), a biopharmaceutical company based in the US, has announced that it...
FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results
US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...
FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising
US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...
FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial
US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...
FibroGen’s Roxadustat Sales in China Rise Despite Price Cut
US firm FibroGen Inc. (NASDAQ: FGEN), which operates subsidiaries in Beijing and Shanghai, released its...